Cue Biopharma has filed a notice of an exempt offering of securities to raise $49,999,927.00 in New Funding.
According to filings with the U.S. Securities and Exchange Commission, Cue Biopharma is raising up to $49,999,927.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.
About Cue Biopharma
Cue Biopharma is a clinical-stage biopharmaceutical company focused on precision immuno-engineering to target functional cures for immune disorders with high unmet need. The company develops novel injectable biologics designed to selectively engage and modulate disease-specific T cells directly within the patients body. Its platform, Immuno-STAT, is intended to target disease-relevant T cells without broad immune modulation, which the company presents as a key differentiator. Cue Biopharmas pipeline includes programs for immunological disorders, including its lead asset CUE-221 for allergic diseases and CUE-401 for autoimmune disease. The company is headquartered in Boston, Massachusetts, and describes itself as building a world-class team to advance its research and clinical development programs.
To learn more, visit https://www.cuebiopharma.com/
LinkedIn: https://www.linkedin.com/company/cuebiopharma
Contact:
Sumita Ray, Chief Legal and Compliance Officer
SOURCE: http://www.intelligence360.io
Copyright (c) 2026 SI360 Inc. All rights reserved.
